ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................JBDM Ver 0.1.63 (23 May 2017) - 2999001/03159405CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120181107W173deBibliographieenBibliographyfrBibliographieEP16196233.72011010520171017enenen282228 P20100105US282247 P20100107US2018110720184520170426201717201809122018372018072420181107201845C12N 15/00 20060101AFI20170117BHEP deVERFAHREN ZUR VERWENDUNG EINES SPEZIFISCHEN ADENOVIRENMITTELS GEGEN ANGIOGENESEenMETHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENTfrPROCÉDÉS POUR L'UTILISATION D'UN AGENT ADÉNOVIRAL ANTIANGIOGENÈSE SPÉCIFIQUEWO-A1-00/61150WO-A2-2007/096882US-A1- 2004 197 860US-A1- 2007 286 845GREENBERGER S ET AL: "Transcription-control led gene therapy against tumor angiogenesis", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 7, 1 April 2004 (2004-04-01) , pages 1017-1024, XP002349281, ISSN: 0021-9738, DOI: 10.1172/JCI20042000711731733.9252177620110105COHEN, Yael100 Stern Street55602 Kiryat-OnoILSHER, Naamit3 Paldi Street76248 RechovotILFEIGE, ErezP.O. Box 17050295 HemedILBANGIO, Livnat1 Daniel Lifshitz Street49776 Petah-TikvaILBREITBART, Eyal27 HaYitzhar Street73127 HashmonaimILVascular Biogenics Ltd.101718637U2261 EP/1 S38 Hasatat St.Modiin 7178106ILVossius & Partner Patentanwälte Rechtsanwälte mbB100751388Siebertstrasse 381675 MünchenDEALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTR